Exemestane and Meldonium Interaction: Monitor | Peptide Database

FDA-approved as a topical treatment for male pattern hair loss. Topical 5% solution is the standard of care, with clinical trials demonstrating significant increases in hair count, particularly at the vertex. Oral low-dose minoxidil is increasingly used off-label. Topical 2% minoxidil is FDA-approved for female pattern hair loss. The 5% formulation has also shown efficacy in women, though with a higher incidence of facial hypertrichosis. Oral low-dose minoxidil (0.625-1.25mg) is used off-label with favorable results. Strongest clinical evidence for regrowth at the vertex and mid-scalp regions, where blood flow improvements from vasodilation have the greatest impact on follicular recovery. Effective for diffuse thinning across the scalp, particularly when combined with a DHT-blocking agent. The systemic delivery of oral minoxidil may offer advantages over topical application for widespread thinning. Used off-label as an adjunctive treatment for alopecia areata, particularly in combination with corticosteroids. Evidence is mixed, and it is not a first-line treatment for this condition.

FDA-approved for reduction of elevated total cholesterol and LDL-C in patients with primary hyperlipidemia, either as monotherapy or in combination with a statin. Reduces LDL by approximately 18% as monotherapy and provides an additional 25% reduction when added to ongoing statin therapy. Widely used off-label by anabolic steroid users to counteract the significant lipid disturbances caused by AAS, particularly oral 17-alpha-alkylated steroids. Oral compounds like oxandrolone can reduce HDL by 50% or more and elevate LDL substantially. Ezetimibe helps blunt LDL elevation while its non-hepatotoxic profile makes it preferable to statins during cycles involving liver-stressing orals. When LDL targets are not achieved with statin monotherapy, adding ezetimibe provides a complementary mechanism of action. The IMPROVE-IT trial demonstrated that the combination of ezetimibe plus simvastatin reduced cardiovascular events compared to simvastatin alone in post-acute coronary syndrome patients. The IMPROVE-IT trial established that adding ezetimibe to simvastatin therapy reduced the composite endpoint of cardiovascular death, major coronary events, and stroke by 6.4% over 7 years in patients with recent acute coronary syndrome. This was the first trial to demonstrate that a non-statin LDL-lowering agent provides incremental cardiovascular benefit. Approved as adjunctive therapy for homozygous familial hypercholesterolemia (HoFH) in combination with statins. Also used in heterozygous FH when statin monotherapy is insufficient to reach LDL targets. Particularly useful in patients who cannot tolerate high-dose statins.